Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGas and diarrhoea are among the most commonly reported gut side effects of Wegovy (semaglutide). Clinical trial data published in the STEP 1 study in the New England Journal of Medicine showed that GI symptoms affected a meaningful proportion of participants, with diarrhoea occurring in roughly 30% of those on semaglutide 2.4mg compared with around 16% on placebo. For most people these symptoms are most noticeable in the first few weeks of treatment or after a dose increase, and they do ease for the majority as the body adjusts. Wegovy is a prescription-only medicine; a clinician assesses your full health picture before any prescription is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial (68 weeks, nearly 2,000 adults with obesity) documented the full side-effect profile of semaglutide 2.4mg against placebo. Diarrhoea was one of the top three GI complaints, alongside nausea and vomiting. Flatulence and burping also appeared more frequently in the semaglutide group than in placebo participants. The NHS semaglutide medicines page lists diarrhoea and wind as common side effects, meaning they affect at least 1 in 10 people taking the medicine. That framing is worth holding onto: common does not mean inevitable, and it does not mean permanent.
The mechanism sits in how semaglutide works. By activating GLP-1 receptors in the gut it slows the movement of food through the stomach and small intestine. Slower gastric emptying changes the fermentation environment further down the digestive tract, which is where excess gas tends to originate. If you are finding that burping and diarrhoea are appearing together on Wegovy, this combination is well documented and relates to the same underlying motility changes. None of this means the gut is being harmed; it is adjusting to a different hormonal signal. The adjustment takes time, and for the large majority of people it is finite.
If you want a fuller picture of how these gut symptoms compare with other effects people notice on treatment, our Wegovy side effects overview covers the whole profile in one place.
There is no clinical trial specifically testing dietary tweaks against Wegovy-related GI symptoms, but prescribers draw on general GI and GLP-1 practice to give sensible guidance. Eating slowly and stopping before feeling full takes advantage of the heightened satiety the medicine already creates. Large, fatty or very rich meals seem to provoke more symptoms in most people; smaller, lower-fat meals spread through the day tend to suit the slower gastric emptying better. High-fibre foods are healthy alongside treatment but can worsen gas if introduced too quickly, so gradual increases work better than an overnight dietary overhaul.
Staying well hydrated matters particularly if diarrhoea is present; dehydration can put strain on the kidneys, and this is a documented concern with semaglutide. Fizzy drinks and gas-producing foods (certain pulses, onions, cruciferous vegetables in large quantities) are worth moderating if flatulence is the main issue. Some people find symptoms cluster around their injection day and ease by the end of the week. If your weekly injection falls before a bank holiday or a day when you know you'll be eating out, mentioning this timing to your prescriber at your next review is entirely reasonable, practical life doesn't pause for treatment schedules.
Detailed management conversations belong with your prescriber, not a website. If symptoms feel unmanageable, a slower titration is sometimes appropriate. Our page on diarrhoea from Wegovy goes deeper on what to expect at each dose stage.
Most gut symptoms on semaglutide are discomfort rather than danger. There are, though, specific patterns that should prompt medical contact without delay. Severe stomach pain that radiates towards the back (with or without vomiting) is the symptom profile associated with acute pancreatitis, which the MHRA flagged as a known but infrequent serious risk in its January 2026 Drug Safety Update on GLP-1 medicines. This is not garden-variety cramping; it tends to be intense and persistent. If it happens, seek urgent care.
If you are experiencing nausea and diarrhoea together on Wegovy, this pairing can accelerate fluid loss, so contact a clinician the same day if you are struggling to keep up with adequate hydration. Signs of an allergic reaction (swelling of the face or throat, difficulty breathing, widespread rash) are a 999 situation regardless of their cause. Gallbladder problems (upper-right abdominal pain, pain after fatty food, possible fever) occur at a higher rate in people losing weight rapidly and are worth raising with a GP rather than managing at home.
For symptoms that are uncomfortable but not alarming (everyday loose stools, intermittent bloating, burping) there is no need to stop treatment without speaking to your prescriber first. Stopping abruptly removes the benefit without allowing time to find a management strategy. If you're mid-consultation and uncertain about your symptoms, our support team is available seven days a week.
Before any prescription is issued at nume, a GPhC-registered Independent Prescriber reads your consultation. Not software, not an automated triage, a named clinician reviews your answers, including your digestive history, the same day. People with certain gastrointestinal conditions, such as gastroparesis or active inflammatory bowel disease, may not be suitable candidates for semaglutide; this is exactly the kind of detail the consultation is designed to surface.
Side effects are part of that conversation from the start, not an afterthought. If you are unsure whether what you are experiencing counts as typical Wegovy diarrhoea or something worth escalating, our prescribers are available through priority aftercare seven days a week to advise whether a slower titration, a temporary pause or a dietary adjustment makes sense. You can also read about the broader Wegovy treatment journey or explore what starting a consultation looks like if you haven't yet. Prescriptions are reviewed clinically before every repeat order; there is no set-and-forget subscription. If suitability or your circumstances change, the review process catches it.
Speak to our prescribers about how semaglutide might suit your health profile, that clinical assessment is where the right decision starts.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.